Illustration by Klawe Rzeczy for TIME. Source images: Bhawika Chhabra—Reuters (Amodei); Yoan Valat—Pool/AFP/Getty Images (Trump); Aaron Ontiveroz—The Denver Post/Getty Images (Hegseth); J. David ...

• Recursion Pharmaceuticals’ stock rises 8% in pre-market to $5.08 after positive trial results. • The Phase 1B/2 TUPELO trial indicates significant reductions in polyp burden for REC-4881, enhancing ...

A weekend leverage flush pushed BTC below $88,000 before a sharp rebound. Bitcoin is trading at a pivotal level that analysts say could determine whether the market holds its broader uptrend or slips ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

Amidst the AI boom transforming various sectors, Recursion Pharmaceuticals (NASDAQ: RXRX), a previously beaten-down AI-biotech, is showing signs of a rebound. Its stock has skyrocketed 25% in the past ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Abstract: Mathematics is filled with conjectures that involve infinite recursive structure, representing complex structures and underlying deep relationships. Discovering such conjectures is crucial ...

Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...

A variation of a puzzle called the “pick-up sticks problem” asks the following question: If I have some number of sticks with random lengths between 0 and 1, what are the chances that no three of ...

AlgoBuddy is an interactive tool for visualizing graph algorithms and recursion trees. It supports BFS, DFS, Dijkstra, Topological Sorting, Fibonacci, Longest Common Subsequence, and more, with ...